Suchergebnisse - "Mertens, Daniel"

PubPharm (30)

1

Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia

enthalten in: Blood | 2022

von Jebaraj, B. | Müller, A. | Dheenadayalan, R. | +15

CommentIn: Blood. 2022 Feb 10;139(6):804-805. - PMID 35142854

2

Triggering T-cell activity in CLL

enthalten in: Blood | 2021

von Mertens, D. | Krönke, J.

CommentOn: Blood. 2021 Jan 14;137(2):216-231. - PMID 33024998

3

Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax

enthalten in: Blood | 2020

von Tausch, E. | Schneider, C. | Robrecht, S. | +21

CommentIn: Blood. 2020 Jun 25;135(26):2333-2334. - PMID 32585022

4

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

enthalten in: Blood | 2019

von Scheffold, A. | Jebaraj, B. | Tausch, E. | +17

CommentIn: Blood. 2019 Aug 8;134(6):496-498. - PMID 31395581

5

FBXW7 mutations reduce binding of NOTCH1, leading to cleaved NOTCH1 accumulation and target gene activation in CLL

enthalten in: Blood | 2019

von Close, V. | Close, W. | Kugler, S. | +10

CommentIn: Blood. 2019 Feb 21;133(8):774-776. - PMID 30792223

6

Ibrutinib-resistant CLL : unwanted and unwonted!

enthalten in: Blood | 2017

von Mertens, D. | Stilgenbauer, S.

CommentOn: Blood. 2017 Mar 16;129(11):1469-1479. - PMID 28049639

7

Gene mutations and treatment outcome in chronic lymphocytic leukemia : results from the CLL8 trial

enthalten in: Blood | 2014

von Stilgenbauer, S. | Schnaiter, A. | Paschka, P. | +29

CommentIn: Blood. 2014 May 22;123(21):3212-4. - PMID 24855188

8

Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial

enthalten in: Blood | 2014

von Stilgenbauer, S. | Schnaiter, A. | Paschka, P. | +29

9

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab : results from the CLL2H trial of the GCLLSG

enthalten in: Blood | 2013

von Schnaiter, A. | Paschka, P. | Rossi, M. | +13

10

NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG

enthalten in: Blood | 2013

von Schnaiter, A. | Paschka, P. | Rossi, M. | +13